Collectively, PEG-IFN-λ1a, which is the pegylated form of IL-29, would be promising anti-metastatic therapeutic to restore the protective function of IL-6/JAK/STAT pathway due to IL10RB activation in CRC. This evidence concerns the gene IL6 and colorectal carcinoma.